- Home
- ADAP vs CHRS Comparison
ADAP vs CHRS Comparison
Compare ADAP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- CHRS
- Stock Information
- Founded
- ADAP 2008
- CHRS 2010
- Country
- ADAP United Kingdom
- CHRS United States
- Employees
- ADAP N/A
- CHRS N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADAP Health Care
- CHRS Health Care
- Exchange
- ADAP Nasdaq
- CHRS Nasdaq
- Market Cap
- ADAP 75.5M
- CHRS 84.2M
- IPO Year
- ADAP 2015
- CHRS 2014
- Fundamental
- Price
- ADAP $0.27
- CHRS $0.90
- Analyst Decision
- ADAP Buy
- CHRS Buy
- Analyst Count
- ADAP 6
- CHRS 3
- Target Price
- ADAP $1.35
- CHRS $4.68
- AVG Volume (30 Days)
- ADAP 644.7K
- CHRS 1.2M
- Earning Date
- ADAP 08-11-2025
- CHRS 08-07-2025
- Dividend Yield
- ADAP N/A
- CHRS N/A
- EPS Growth
- ADAP N/A
- CHRS N/A
- EPS
- ADAP N/A
- CHRS N/A
- Revenue
- ADAP $179,639,000.00
- CHRS $272,251,000.00
- Revenue This Year
- ADAP N/A
- CHRS N/A
- Revenue Next Year
- ADAP $35.48
- CHRS $106.56
- P/E Ratio
- ADAP N/A
- CHRS N/A
- Revenue Growth
- ADAP 878.53
- CHRS 19.87
- 52 Week Low
- ADAP $0.20
- CHRS $0.66
- 52 Week High
- ADAP $1.48
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- ADAP 56.59
- CHRS 59.04
- Support Level
- ADAP $0.23
- CHRS $0.73
- Resistance Level
- ADAP $0.28
- CHRS $0.82
- Average True Range (ATR)
- ADAP 0.02
- CHRS 0.04
- MACD
- ADAP 0.00
- CHRS 0.02
- Stochastic Oscillator
- ADAP 87.96
- CHRS 88.02
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.